Treatments and Recovery | Fertility and Immunology | Reproductive Endocrinology

Progesterone and Endometriosis

Why the Hormone, and the Form It Comes In, Both Matter

How progesterone controls the lining of the uterus, why endometriosis makes the body stop listening to it, and a plain-language guide to the many progesterone and progestin formulations: what they are, how strong they are, and which ones actually treat the disease.

Medically reviewed by Andrea Vidali, MD – Reproductive Endocrinologist, Reproductive Immunologist, and Endometriosis and Adenomyosis Excision Surgeon, ESSI. Estimated reading time: 15 minutes.

Progesterone is the hormone that is supposed to keep the lining of the uterus calm, organized, and under control. In endometriosis, that signal breaks down, and understanding how it breaks, and how the many forms of progesterone and its synthetic cousins differ, explains a great deal about why treatment succeeds or fails.

This is a guide to two things patients are rarely told clearly: why endometriosis makes the body stop responding to its own progesterone, and what the confusing menu of “progesterone” products, natural and synthetic, oral and vaginal, weak and strong, actually means for the disease.

Part 1: What Progesterone Is Supposed to Do

Every cycle, estrogen builds the lining of the uterus up, and progesterone is the counter-signal that tells it to stop growing and organize itself. In healthy tissue, progesterone does four jobs at once. It opposes estrogen, in part by switching on an enzyme, 17-beta-HSD type 2, that converts potent estradiol into a much weaker estrogen, essentially disposing of estrogen locally. It transforms the lining into a receptive state for pregnancy, a process called decidualization. It calms inflammation. And it keeps bleeding controlled. Progesterone, in short, is the brake on an estrogen-driven tissue.

How progesterone’s four main actions differ between healthy tissue and endometriosis

Progesterone Action	In Healthy Tissue	In Endometriosis
Opposes estrogen	Switches on 17-beta-HSD type 2, breaking down estradiol locally	The enzyme fails to switch on; estradiol accumulates and feeds the disease
Transforms the lining (decidualization)	Prepares a receptive lining for pregnancy	Decidualization is poor, contributing to implantation failure and infertility
Calms inflammation	Keeps local inflammation in check	Inflammation persists and is fueled by excess estrogen
Controls bleeding	Keeps bleeding regulated	Bleeding control is impaired

Part 2: Progesterone Resistance: Why the Body Stops Listening

Endometriosis is, at its core, a disease in which the tissue stops responding to progesterone, a state called progesterone resistance. It is easy to hear that phrase and picture “not enough of the hormone,” but that is not what it means. The progesterone is there; the tissue no longer obeys it.

More than “fewer receptors”

The best-known finding is that endometriotic tissue has reduced progesterone receptors, especially the loss of one form, PR-B, silenced by a chemical tag on the gene (methylation). That is real, but it is the shallowest part of the story, and on its own it is the weakest evidence. The stronger evidence is functional: the tissue fails to carry out progesterone’s instructions even when you account for the receptors. The clearest example is that enzyme that disposes of estrogen; in endometriosis, progesterone fails to switch it on, so estradiol is never broken down and instead accumulates, feeding the very disease progesterone is meant to restrain.

A rewiring, not a shortage

Underneath sits something more striking: a stable reprogramming of the cell. In endometriosis the tissue undergoes an epigenetic switch: one master control factor (GATA2), which normally drives the progesterone response, is turned down, while another (GATA6) is turned up and actively blocks the tissue’s ability to hear hormones. When researchers force this switch into healthy cells, the healthy cells start behaving like endometriosis. A related change over-expresses one form of the estrogen receptor, which further suppresses the progesterone signal and fuels inflammation. The result is a self-reinforcing state that turns the progesterone program off and the estrogen-and-inflammation program on.

Progesterone resistance is the signal being ignored, not the signal being absent.

This has direct consequences. The lining decidualizes poorly, which contributes to implantation failure and infertility, and the same defect has now been demonstrated in adenomyosis, so it bridges both conditions. Clinically, a meaningful number of women simply do not get relief from progestin therapy, and a marker called BCL6 can flag this resistant, inflamed endometrium. One honest note: resistance is a spectrum and is partial, not absolute. The concept earns its place precisely because it is measurable, you can see the enzyme fail to switch on, see the decidualization falter, rather than being a vague label.

Commentary – Andrea Vidali, MD

“When a patient is told she has ‘progesterone resistance,’ that is not a shrug or an excuse. It is a specific, measurable failure of the tissue to obey a hormone that is present in normal amounts. The practical trap is the instinct to answer resistance by simply adding more progesterone, that is like turning up the volume for someone whose hearing aid is switched off. What resistance calls for is a treatment strong enough, and delivered well enough, to be heard, and, when it comes to fertility, an honest reckoning that the lining itself may need help, not just the hormone level.”

Part 3: Natural Progesterone Is Not the Same as a Progestin

Part of the confusion patients face is linguistic. “Progesterone” usually means the natural, bioidentical hormone, identical to what your body makes. “Progestins” (or progestogens) are synthetic cousins, engineered to be stronger and longer-acting. They are not interchangeable, and they are used for very different purposes.

Two different tools that share a name

Feature	Natural (Bioidentical) Progesterone	Synthetic Progestins
Source	Identical to the body’s own hormone	Chemically modified, engineered for strength and duration
Oral potency	Weak; less than 10 percent absorbed	Strong and reliable
Main use	Luteal phase and IVF support, early pregnancy, menopausal HRT	Suppressing endometriosis
Off-target activity	None; identical to the natural hormone	Varies by chemical family (androgenic, anti-androgenic, and so on)

Natural (bioidentical) progesterone

Natural micronized progesterone is the body’s own hormone in a form processed for absorption. Taken by mouth, it is weak, less than ten percent survives the liver’s first pass, its metabolites cause drowsiness, and it takes very high doses to do much. Given vaginally, it works through a “uterine first-pass” effect that delivers high concentrations to the uterus itself while keeping blood levels low, which is why the vaginal route is favored for supporting an early pregnancy. Given by injection, it produces high, steady blood levels but is painful. Its real roles are luteal-phase and IVF support, protecting an early pregnancy, and shielding the lining during menopausal hormone therapy. It is not used to suppress endometriosis, it is simply too weak for that job, and does not reliably switch the disease off.

Synthetic progestins

Progestins are built for potency and staying power. They can quiet and thin the lining reliably enough to control disease, which is why they, not natural progesterone, are the medical mainstay of endometriosis. The trade-off is that, depending on their chemical origin, they carry off-target hormonal activities: some are mildly androgenic, some anti-androgenic, some touch the stress-hormone or salt-balancing receptors. Those side activities are exactly what the next section maps.

The distinction that matters at the bedside

If you are told “your progesterone is low, take some progesterone,” that is fertility and luteal logic, supporting a cycle or a pregnancy. It is a different problem from treating endometriosis, which needs suppression, and where resistance means more of the same hormone may not be the answer. Knowing which problem is being solved keeps the treatment matched to the goal.

Part 4: A Guide to the Formulations

“Potency” is not a single number. It blends how much of the lining a drug transforms and suppresses with its off-target hormonal activities, and the practical measure is the clinical dose and effect rather than any one ranking. The table below groups the progesterone and progestin options by chemical family, which, usefully, predicts their off-target effects.

Progesterone and progestin formulations by chemical family

Class (Chemical Origin)	Examples (Brands)	Progestogenic Strength	Notable Off-Target Activity	Main Clinical Role
Natural progesterone	Micronized progesterone (Prometrium, Utrogestan; Crinone/Endometrin vaginal; progesterone-in-oil IM)	Weak by mouth (less than 10 percent absorbed); strong locally by vagina or injection	None off-target (identical to your own); mild sedation from metabolites	Luteal/IVF support, early pregnancy, menopausal HRT; not disease suppression
Retroprogesterone	Dydrogesterone (Duphaston)	Moderate; orally active; does not stop ovulation	Pure progestogen; no androgen effect	Luteal support, miscarriage prevention; symptom relief while sparing ovulation
17-OH-progesterone (pregnanes)	Medroxyprogesterone acetate (Provera, Depo-Provera); cyproterone; megestrol	Moderate to strong (MPA stops ovulation at about 10 mg/day)	Anti-androgenic; some glucocorticoid activity	MPA: endometriosis pain (first-line, economical); depot form requires bone-density caution
19-nor-progesterone	Nomegestrol acetate; trimegestone; nestorone	Strong, “pure” progestogens	Little to no off-target activity	Contraception and HRT (not a US endometriosis mainstay)
19-nortestosterone: estranes	Norethindrone/norethisterone; norethindrone acetate (Aygestin); lynestrenol	Norethindrone acetate is potent (stops ovulation at low dose)	Mildly androgenic; slight estrogenic	Endometriosis (NETA is FDA-approved), heavy bleeding, contraception
19-nortestosterone: gonanes	Levonorgestrel (oral; LNG-IUS 52 mg); desogestrel; gestodene; norgestimate	Levonorgestrel strong; newer gonanes more receptor-selective	Levonorgestrel androgenic; desogestrel/norgestimate less so	LNG-IUS delivers progestin locally for endometriosis/adenomyosis; contraception
Dienogest (hybrid)	Dienogest (Visanne; in the US only within Natazia, combined with estrogen)	Strong effect on the lining at just 2 mg despite low receptor affinity (high free drug levels)	Anti-androgenic; the exception among 19-nortestosterone drugs	Endometriosis first-line; shown as effective as GnRH agonists
Spironolactone derivative	Drospirenone (Slynd, Yaz)	Moderate	Anti-mineralocorticoid and anti-androgenic	Contraception, PMDD; a progestin-only option

A note on the table: “Potency” is multidimensional. A drug’s progestogenic strength (how completely it transforms and suppresses the lining) is separate from its off-target activities, and both differ by route and dose. The safest comparison is by clinical effect, not a single number.

Which ones treat endometriosis, and how

Across major guidelines, including the 2022 ESHRE guideline, progestins (most often dienogest or medroxyprogesterone acetate) and combined hormonal contraceptives are the recommended first-line medical treatment for endometriosis-associated pain, with a strong evidence base. The levonorgestrel intrauterine system is a first-line hormonal option that delivers progestin directly to the uterus. GnRH agonists and antagonists are effective but, because of their menopausal side-effect profile, are reserved as second-line, usually with “add-back” therapy to protect bone; aromatase inhibitors are added for pain that resists everything else.

Endometriosis treatment options: dose, guideline status, and notes

Drug	Typical Dose/Route	Guideline Status	Notes
Dienogest	2 mg/day, oral	First-line	Receptor-selective and anti-androgenic; anti-inflammatory; as effective as GnRH agonists without the menopausal cost; not sold standalone in the US
Norethindrone acetate	5 to 15 mg/day, oral	First-line (US workhorse)	FDA-approved for endometriosis; inexpensive; has data in adenomyosis
Medroxyprogesterone acetate	10 to 30 mg/day oral, or 150 mg IM every 3 months	First-line	Effective and economical; the depot form can cause reversible bone-density loss and irregular bleeding
Levonorgestrel IUS (52 mg)	Intrauterine, about 5 to 8 years	First-line hormonal	Local delivery thins and atrophies the lining; strong for coexisting adenomyosis and heavy bleeding
Drospirenone	4 mg/day, oral	Option	Anti-androgenic and anti-mineralocorticoid; less endometriosis-specific data
Combined hormonal contraceptives	Oral/ring/patch, often continuous	First-line	Contain estrogen; useful for pain but can underperform for adenomyosis-type bleeding
GnRH agonists/antagonists	Injection or oral	Second-line	Reserve for refractory disease; use add-back therapy for bone and menopausal effects
Aromatase inhibitors	Oral, with a progestin or pill	Refractory pain	Cut local estrogen production when other options fail

Why dienogest keeps coming up

Dienogest is worth singling out because it threads a needle. It is chemically a 19-nortestosterone progestin, the family that tends to be androgenic, yet it is the one member that is anti-androgenic instead. It binds the progesterone receptor relatively weakly but reaches high free levels in the body, so it exerts a strong, selective effect on the lining at a small 2 mg dose. It is anti-inflammatory and anti-angiogenic, and it suppresses the nerve-growth signals that drive endometriosis pain. In head-to-head terms it matches GnRH agonists for pain relief without forcing a woman into a temporary menopause. Its one practical drawback in the United States is availability: it is not sold here as a standalone drug, only bundled with estrogen.

Commentary – Andrea Vidali, MD

“There is no single best progestin, there is a best fit for a given patient. I weigh what her body will tolerate, whether she is trying to conceive, whether adenomyosis and heavy bleeding are in the picture, and how her disease has behaved. Dienogest is often my preference where it can be obtained, because its profile is so well matched to this disease; norethindrone acetate is the reliable American workhorse; the levonorgestrel IUD earns its place when the uterus itself is bleeding heavily. And I am candid with every patient about the ceiling of medical therapy: these drugs manage the disease and can do so very well, but no pill removes it. That is a separate conversation, and an honest one.”

Take-Home Messages

• Progesterone is the brake on an estrogen-driven lining: it opposes estrogen, transforms the lining, calms inflammation, and controls bleeding.
• Progesterone resistance means the signal is ignored, not absent. It is a measurable, functional failure, and a stable epigenetic rewiring, not simply “low progesterone.”
• Natural progesterone and synthetic progestins are different tools. Natural progesterone supports cycles and pregnancy; progestins suppress disease.
• “Potency” is multidimensional. A progestin’s strength on the lining is separate from its off-target effects, which track its chemical family.
• Progestins are first-line for endometriosis. Dienogest, norethindrone acetate, MPA, and the levonorgestrel IUD lead; dienogest is uniquely well matched but limited in the US.
• Medicine manages endometriosis; it does not remove it. Knowing which goal you are treating, symptoms, fertility, or the disease itself, keeps the tool matched to the aim.

Frequently Asked Questions

Is progesterone the same thing as a progestin?

No. “Progesterone” usually means the natural, bioidentical hormone identical to what your body makes. “Progestins” (or progestogens) are synthetic versions engineered to be stronger and longer-acting. They are used for different purposes: natural progesterone mainly supports cycles and pregnancy, while progestins are the mainstay of treating endometriosis.

What is progesterone resistance in endometriosis?

It is a state in which the tissue stops responding to progesterone even though the hormone is present in normal amounts. It involves reduced receptors, a failure to carry out progesterone’s instructions (such as switching off local estrogen), and a stable epigenetic “rewiring” that turns the progesterone program off and the estrogen-and-inflammation program on. It is measurable, not just a label.

If I have “low progesterone,” will taking progesterone treat my endometriosis?

Not usually. Taking progesterone is fertility and luteal logic, it supports a cycle or an early pregnancy. Endometriosis needs suppression, and because the tissue is resistant, simply adding more of the same hormone often does not reach the problem. The two are different goals with different treatments.

What is the best progestin for endometriosis?

There is not one universal best, there is a best fit. Dienogest is the most disease-specific and is first-line in much of the world; norethindrone acetate is the reliable US option; medroxyprogesterone acetate is effective and economical; and the levonorgestrel IUD is excellent when heavy bleeding or adenomyosis is also present. The right choice depends on your history, tolerance, and fertility goals.

Why is dienogest considered special?

It is the one progestin in the 19-nortestosterone family that is anti-androgenic rather than androgenic. It works strongly and selectively on the lining at a low 2 mg dose, is anti-inflammatory, and calms the nerve-growth signals behind endometriosis pain, matching GnRH agonists for pain relief without causing a temporary menopause. In the US it is only available combined with estrogen, which limits its use.

Is natural (bioidentical) progesterone used to treat endometriosis?

Generally no. Natural micronized progesterone is too weak by mouth to suppress the disease and does not reliably switch it off. Its roles are luteal-phase and IVF support, protecting an early pregnancy, and protecting the lining during menopausal hormone therapy.

What does “potency” mean for a progestin?

It blends two separate things: how completely the drug transforms and suppresses the lining, and its off-target hormonal activities (androgenic, anti-androgenic, and so on). Potency also depends on the route and dose, so the most reliable comparison is the clinical effect at a given dose, not a single ranking.

Do progestins cause side effects, and why do they differ?

Yes, and the differences trace to chemical origin. Progestins derived from testosterone can be mildly androgenic (acne, mood, lipid effects); those derived from 17-OH-progesterone tend to be anti-androgenic with some stress-hormone activity; dienogest and drospirenone are anti-androgenic. Matching the side-effect profile to the individual is part of choosing well.

Do these treatments affect my ability to get pregnant later?

Most are reversible, fertility typically returns after stopping. Some, like dydrogesterone, do not suppress ovulation and can relieve symptoms while preserving a cycle. The levonorgestrel IUD and ovulation-suppressing progestins are for symptom control, not for use while actively trying to conceive. If pregnancy is the goal, the plan should be built around that from the start.

Will a progestin cure my endometriosis?

No. Progestins can control the disease and its symptoms, sometimes very effectively, but they do not remove it, symptoms often return when the medication stops. Definitive treatment of the disease itself is a separate conversation, and one worth having with a specialist.

Final Commentary – Andrea Vidali, MD

“The deepest misunderstanding about progesterone and endometriosis is the idea that the problem is a shortage of the hormone. It is not. The problem is that the disease has taught the tissue to stop listening, and it has done so through a specific, traceable biology we can now read.

That changes how we should think about treatment. The goal is not to flood the body with more of a signal it is ignoring, but to choose an agent strong enough and matched well enough to be heard, and to be clear-eyed about what medicine can and cannot do. Progestins manage this disease, often beautifully. They do not erase it. Every woman deserves to know which of those two things she is being offered, and to have the full menu explained, not just the one drug nearest to hand.”

The Most Important Step Is the First One

If endometriosis is shaping your treatment decisions, pain, bleeding, or fertility, ESSI can help you match the therapy to your goals.

Request a Consultation
internationalendo.com | +1 516-584-8710

Medical disclaimer: This article is for education and is not a substitute for medical advice, diagnosis, or treatment. Speak with a qualified clinician about your individual situation and before changing any medication.

Selected References

1. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7-S16; and Maturitas. 2008;61:171-180.
2. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208.
3. Bulun SE, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006; and Bulun SE. 17-beta-HSD type 2 deficiency and progesterone resistance in endometriosis. Semin Reprod Med. 2010.
4. Zeitoun K, Takayama K, Sasano H, et al. Deficient 17-beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17-beta-estradiol. J Clin Endocrinol Metab. 1998;83(12):4474-4480.
5. Dyson MT, Roqueiro D, Monsivais D, et al. Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. PLoS Genet. 2014;10(3):e1004158.
6. Dysregulated expression of GATA2 and GATA6 in adenomyosis: implications for impaired endometrial receptivity. F&S Science. 2023.
7. Cheng YH, Imir A, Fenkci V, Yilmaz MB, Bulun SE. Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial HSD17B2 and its regulator Sp1. Am J Obstet Gynecol. 2007;196(4):391.e1.
8. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009.
9. Treatment of endometriosis: a review with comparison of 8 guidelines (progestins first-line; dienogest and MPA). BMC Womens Health. 2021.
10. Gezer A, Oral E. Progestin therapy in endometriosis. Women’s Health (Lond). 2015;11(5):643-652.
11. Dienogest reviews: antiandrogenic 19-nortestosterone progestin; transformation dose approximately 6 mg/cycle; strong endometrial effect at 2 mg/day. Oncotarget. 2017; and dienogest efficacy trials.
12. Micronized progesterone pharmacokinetics: oral bioavailability less than 10 percent due to hepatic first-pass; vaginal uterine first-pass effect; IM progesterone. Stanczyk 2013; Fertil Steril 1993; DDDT 2019.
13. Ovulation-inhibition and endometrial transformation doses of progestins (systematic review). Reproductive BioMedicine / Contraception.